Beyond Type 2 Inflammation: The Next Decade of IL-4Rα Therapeutics and the Humanized Mouse Model Breakthrough

In 2026, nearly a decade after the first IL-4Rα monoclonal antibody, dupilumab (Dupixent®), received regulatory approval, this target continues to reshape the treatment landscape for autoimmune and inflammatory diseases at a pace that has exceeded expectations.

Dupilumab has delivered exceptional clinical and commercial value across a rapidly expanding range of indications. In 2025, Dupixent achieved global net sales of $17.8 billion and served more than 1.4 million active patients worldwide. First-quarter sales reached $4.9 billion in 2026 alone ^[1].

Initially approved for atopic dermatitis, Dupixent has since expanded into asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease, bullous pemphigoid, and other diseases including dermatology, respiratory medicine, and gastroenterology. More recent approvals include pediatric chronic spontaneous urticaria and allergic fungal rhinosinusitis (AFRS), making Dupixent the first drug specifically approved for AFRS ^[1].

Figure 1. Dupixent has received approvals across multiple indications ^[1].

The evolution of IL-4Rα from an atopic dermatitis target into a cross-disease therapeutic axis is opening a new chapter for the field. As dupilumab approaches its patent cliff, Chinese-developed monoclonal antibodies move toward commercialization, and emerging modalities such as bispecific antibodies reshape competition, the IL-4Rα market is entering a period of profound transformation.

Where will the decisive breakthroughs of the next decade emerge?

Why IL-4Rα Is a Central Hub in Type 2 Inflammation

To understand why the IL-4Rα field continues to expand, it is necessary to examine the target's unique biological role.

Type 2 inflammation is driven largely by Th2 cytokines, particularly IL-4 and IL-13, and underlies chronic diseases such as atopic dermatitis and asthma, which affect approximately 204 million and 262 million people worldwide, respectively ^[2-3].

IL-4Rα is the shared receptor subunit for IL-4 and IL-13 signaling. By forming two receptor complexes, it activates the JAK1/2/3–STAT6 pathway, promoting Th2-cell differentiation, IgE class switching, and eosinophil recruitment.

Blocking IL-4Rα therefore inhibits both pathways at an upstream signaling hub. This broader mechanism distinguishes IL-4Rα blockade from therapies targeting a single downstream mediator and supports multiple drug formats, including monoclonal antibodies, bispecific antibodies, and inhaled nanobodies.

Dupilumab binds IL-4Rα and simultaneously inhibits IL-4 and IL-13 signaling, delivering significant and consistent efficacy across multiple Phase III clinical studies ^[4-6].

Figure 2. Mechanism of action of dupilumab within the type 2 inflammatory cascade ^[5].

From a Single Blockbuster to a Crowded R&D Landscape

Dupilumab has built a substantial first-mover advantage, but its core patents are expected to begin expiring around 2031. Meanwhile, the IL-4Rα monoclonal antibody market in China has become intensely competitive, led by two major players and followed by several rapidly advancing candidates.

Keymed Biosciences' stapokibart was approved in September 2024, becoming the first domestically developed IL-4Rα monoclonal antibody approved in China. It entered the market with seasonal allergic rhinitis as a differentiated indication, generated approximately RMB 170 million in net sales during the first half of 2025, and was included in China's National Reimbursement Drug List by year-end.

Real-world evidence has also shown encouraging activity in allergic rhinitis, allergic fungal rhinosinusitis, and bullous pemphigoid in older adults. In one study of moderate-to-severe seasonal allergic rhinitis, the median nasal symptom score decreased from 8 to 4 over 12 weeks, with an adverse-event incidence of 6.3% ^[7-8].

IL-4Rα antibodies from Akeso, 3SBio, Mabgeek Biotechnology, Simcere Pharmaceutical, Genrix Biopharmaceutical, and other companies have also entered regulatory review or are approaching filing. The competitive intensity increasingly resembles the early development of the PD-(L)1 field.

Figure 3. IL-4Rα-targeted therapeutics in late-stage clinical development, under regulatory review, or approved for marketing.

Real-World Efficacy Gaps Drive Product Innovation

Although dupilumab has delivered significant improvements in the treatment of atopic dermatitis and asthma, real-world studies indicate that a substantial proportion of patients still fail to achieve the most stringent treatment goals, such as EASI-90 or a pruritus NRS score of 0 or 1, even after long-term treatment ^[9-10].

By comparison, JAK inhibitors such as upadacitinib and abrocitinib can simultaneously suppress multiple cytokine signaling pathways. In head-to-head clinical trials, they have frequently demonstrated a faster onset of action and higher rates of achieving stringent treatment targets ^[11-12].

In chronic obstructive pulmonary disease (COPD), dupilumab is effective in patients with type 2 inflammation characterized by elevated eosinophil levels, who account for approximately 20%–40% of the COPD population. However, its efficacy is limited in patients with non-type 2 inflammation, including neutrophilic or mixed inflammatory phenotypes. Severe and complex conditions such as asthma–COPD overlap (ACO) also continue to lack targeted biologic therapies ^[13].

Figure 4. JAK inhibitors demonstrated a faster onset of action and higher rates of achieving stringent treatment targets in head-to-head clinical trials ^[11].

These efficacy gaps are driving IL-4Rα-targeted therapies beyond single-target blockade and toward multi-target synergy, extended dosing intervals, and localized delivery.

Next-Generation Molecular Innovation Led by Long-Acting and Bispecific Antibodies

• Long-acting therapies are critical for improving treatment adherence. Compared with established IL-4Rα therapies such as dupilumab, which typically require dosing every two weeks in adults, next-generation candidates are being developed to reduce treatment frequency. Comekibart (MG-K10), positioned by its developer as a potential first long-acting IL-4Rα monoclonal antibody, supports once-every-four-weeks dosing. Meanwhile, Aclaris Therapeutics' TSLP/IL-4Rα bispecific antibody ATI-052 demonstrated an estimated half-life of approximately 45 days in a Phase I trial, supporting the potential for dosing intervals of up to three months, although this remains to be validated in patient studies ^[15–16].
• Bispecific antibodies aim to improve efficacy by blocking multiple pathways simultaneously. Innovent Biologics' IBI3002, an IL-4Rα/TSLP bispecific antibody, demonstrated significant improvements in FEV1 and multiple inflammatory biomarkers in a Phase Ib asthma-focused clinical trial. Other candidates, including Akeso's AK139 which targets both IL-4Rα/ST2 and Zymeworks' ZW-1528 targeting both IL-4Rα/IL-33, are also progressing steadily ^[17].
• Localized inhaled delivery and antibody–drug conjugate technologies offer new strategies for reducing systemic exposure. Inhaled antibodies such as Hengrui Pharmaceuticals' SHR-4597 and Shanghai Novamab Biopharmaceuticals' LQ-036 are designed to reduce adverse effects through localized administration. ADC molecules that leverage the internalization properties of IL-4Rα, including SIM0708 and XM147-SN38, are also under development, with expansion being explored into non-respiratory indications such as glioblastoma.

Figure 5. Evolution of next-generation IL-4Rα molecular formats.

However, multi-target strategies remain difficult to translate into superior clinical outcomes. An IL-4Rα/IL-31 bispecific antibody acquired by Johnson & Johnson in a $1.25 billion transaction was discontinued early in a Phase IIb trial after failing to meet the specified efficacy threshold ^[18].

Although dual-target approaches have shown the potential to suppress Th2 inflammation synergistically in early research, no bispecific antibody has yet demonstrated significantly greater efficacy than dupilumab in a head-to-head clinical trial.

Converting theoretical multi-target synergy into meaningful patient benefit therefore remains a central challenge. Future advances may depend on improved drug delivery and biomarker-guided patient stratification.

Therapeutic Potential Beyond Inflammatory Diseases

Beyond established type 2 inflammatory diseases, the therapeutic potential of IL-4Rα is expanding into a broader range of fields.

In metabolic diseases, IL-4Rα signaling in non-hematopoietic cells is involved in regulating adipose tissue inflammation and insulin sensitivity. In the autoimmune disease bullous pemphigoid, IL-4Rα-targeted therapies may provide an alternative to systemic glucocorticoids ^[19].

In cancer immunology, IL-4Rα/IL-13Rα1 expression is elevated in multiple solid tumors. IL-4 signaling can promote M2 macrophage polarization and contribute to the formation of an immunosuppressive tumor microenvironment. Early clinical research combining dupilumab with PD-1/PD-L1 inhibitors in non-small cell lung cancer has produced preliminary efficacy signals, including substantial responses in some patients ^[20].

IL-4Rα is gradually evolving into a central therapeutic hub spanning inflammation, cancer immunology, and other disease areas.

Figure 6. Dupilumab combined with PD-1/PD-L1 inhibitors demonstrated preliminary efficacy signals in NSCLC ^[20].

Dual-Humanized IL-4/IL-4Rα Mice: A Better Model for IL-4Rα Therapeutics

As IL-4Rα-targeted therapeutics advance from conventional monoclonal antibodies toward bispecifics, long-acting formulations, and combination regimens, preclinical evaluation has grown correspondingly complex. A key translational barrier is the modest sequence identity of roughly 51% between the extracellular domains of human and mouse IL-4Rα. Highly humanized antibodies such as dupilumab typically fail to bind mouse IL-4Rα, so conventional wild-type mice cannot reproduce human pharmacokinetics or pharmacological responses.

To close this gap, Cyagen developed the huIL4/huIL4RA dual-humanized mouse model (C001834), in which the endogenous mouse Il4 and Il4ra genes are replaced with their human counterparts to drive functional co-expression of human IL-4 and IL-4Rα in vivo. Validation studies show that the model reliably recapitulates Th2 inflammatory phenotypes in both oxazolone-induced atopic dermatitis and ovalbumin-induced allergic asthma. Critically, it also exhibits a clear dose-dependent pharmacodynamic response to dupilumab, faithfully reflecting the drug's mechanism of action and translating efficacy differences relevant to human patients.

Figure 7. Summary of validation data from the huIL4/huIL4RA dual-humanized mouse model.

As competition in the IL-4Rα field becomes increasingly crowded and the requirements for preclinical evaluation continue to rise, animal models capable of accurately reproducing the human immune microenvironment and supporting the evaluation of complex molecular formats have become indispensable tools in drug development.

Cyagen's huIL4/huIL4RA dual-humanized mouse model and broader portfolio of multi-target humanized models provide in vivo platforms for evaluating IL-4Rα-targeted therapies and other drug candidates for type 2 inflammatory diseases, helping accelerate their progression toward clinical translation.

Figure 8. Broader portfolio of humanized models for evaluating IL-4Rα-targeted therapies.

👉 View Full Validation of the huIL4/huIL4RA Dual-Humanized Model

👉 Search Our Repository of 38,000+ Ready-to-Use Mouse Models

👉 Consult with Our Experts to Design Your Next High-Impact In Vivo Study

Reference

[1] Regeneron Pharmaceuticals, Inc. Regeneron reports first quarter 2026 financial and operating results [Internet]. Tarrytown (NY): Regeneron Pharmaceuticals, Inc.; 2026 Apr 29 [cited 2026 Jul 16]. Available from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2026-financial-and-operating

[2] Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190(1):55-61. doi:10.1093/bjd/ljad339

[3] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.

[4] Gao P, et al. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025;22(2):123-145. doi:10.1038/s41423-025-01261-2.

[5] Hamilton JD, et al. Dupilumab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e13899. doi:10.1111/cts.13899.

[6] Bhatt SP, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Blood Eosinophils. N Engl J Med. 2024;390(24):2275-2287. doi:10.1056/NEJMoa2303951.

[7] Keymed Biosciences Inc. Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum. Press release. 2025 Aug 26. Available from: https://en.keymedbio.com/en/newsd.html?id=74&type=1

[8] Zhang Y, et al. Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial. Nat Med. 2025.

[9] Multiple real-world studies and systematic reviews on long-term outcomes with dupilumab in atopic dermatitis (2025-2026 publications in J Allergy Clin Immunol and related journals).

[10] TARGET-DERM AD Registry analyses on therapeutic inertia and suboptimal disease control in moderate-to-severe atopic dermatitis (2024-2026 registry publications).

[11] Blauvelt A, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatol. 2021;157(9):1047-1055.

[12] Silverberg JI, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384(12):1101-1112.

[13] Bhatt SP, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Blood Eosinophils. N Engl J Med. 2024;390(24):2275-2287.

[14] Sagayaraj MJ, Panneerselvam S, Jeganathan HR, Theivendren P. Advances in asthma-COPD overlap treatment: A comprehensive review of therapeutic approaches. Respir Med. 2025;250:108542. doi:10.1016/j.rmed.2025.108542

[15] Aclaris Therapeutics, Inc. Aclaris Therapeutics Announces Positive Full Top Line Results from First-in-Human Phase 1a Trial of ATI-052. Press release. April 28, 2026. Available from: https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-positive-full-top-line-first

[16] Aclaris Therapeutics, Inc. Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis for ATI-052. Press release. January 12, 2026. Available from: https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-initiates-phase-1b-proof-concept-trial

[17] Ren A, Chang C, Sun X, et al. B32-36 IBI3002, A First-in-class Anti-IL-4RΑ/TSLP Bispecific Antibody in Patients With Mild-To-Moderate Asthma: A Randomized, Double-Blind, Placebo-Controlled, Single Dose Phase Ib Study. Am J Respir Crit Care Med. 2026;212(Suppl 1):Aamag162.476. doi:10.1093/ajrccm/aamag162.476

[18] Johnson & Johnson. Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study. Press release. December 2025. Available from: https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study

[19] Successful use of stapokibart as a biological therapy for allergic fungal rhinosinusitis: a case report. Frontiers in Allergy. 2025. https://doi.org/10.3389/falgy.2025.1746033

[20] LaMarche NM, Hegde S, Park MD, et al. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature. 2024;625(7993):166-174. doi:10.1038/s41586-023-06797-9. PMID: 38057662.